On the other side, active cellular immunotherapy focuses on rebuilding the intrinsic immune microenvironment to exert its antineoplastic potency against PLC, which is superior in the risk reduction of uncertain triggered immune response while more in need of comprehensive considerations on the tumor immunogenicity and host’s immune status. The gene discussed is HSPG2; the disease is neoplasm.